Table 4.
Response categories for patients monitored by CE-CT and FDG-PET/CT .
| Treatment Actions | Response Categories a | |||||||
|---|---|---|---|---|---|---|---|---|
| Study Groups | CR/CMR | PR/PMR | SD/SMD | PD/PMD | MR/MMR | EA/EMA | ||
| CE-CT | Scans followed by progression-induced treatment change b (n = 44) | 0 (0) | 1 (2.3) | 8 (18.2) | 34 (77.3) | 0 (0) | 1 (2.3) | |
| Total scans c (N = 286) | 11 (3.8) | 24 (8.4) | 202 (70.6) | 43 (15) | 2 (0.7) | 4 (1.4) | ||
| PET/CT | Scans followe by progression-induced treatment change b (n = 22) | 0 (0) | 0 (0) | 0 (0) | 21 (95.5) | 1 (4.5) | 0 (0) | |
| Total scans c (N = 189) | 42 (22.2) | 45 (23.8) | 59 (31.2) | 35 (18.5) | 4 (2.1) | 4 (2.1) | ||
CE-CT: contrast-enhanced computed tomography; FDG-PET/CT: fluorodeoxyglucose positron emission tomography with integrated computed-tomography; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; MR: mixed response; EA: equivocal answer; CMR: complete metabolic response; PMR: partial metabolic response; SMD: stable metabolic disease; PMD: progressive metabolic disease; MMR: mixed metabolic response; EMA: equivocal metabolic answer. a Data have been shown as frequency (percentage) of each line. b Progression-induced treatment change defined as progression observed in imaging and/or clinical progression resulting in treatment change. c Scans from opposite modality were excluded in both study groups.